Unknown

Dataset Information

0

Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review.


ABSTRACT: Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer.

SUBMITTER: Leong DP 

PROVIDER: S-EPMC10443114 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: <i>JACC: CardioOncology</i> State-of-the-Art Review.

Leong Darryl P DP   Cirne Filipe F   Aghel Nazanin N   Baro Vila Rocio C RC   Cavalli Germano D GD   Ellis Peter M PM   Healey Jeff S JS   Whitlock Richard R   Khalaf Dina D   Mian Hira H   Jolly Sanjit S SS   Mehta Shamir R SR   Dent Susan S  

JACC. CardioOncology 20230711 4


Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the  ...[more]

Similar Datasets

| S-EPMC8352246 | biostudies-literature
| S-EPMC9830230 | biostudies-literature
| S-EPMC9270612 | biostudies-literature
| S-EPMC10635896 | biostudies-literature
| S-EPMC11372032 | biostudies-literature
| S-EPMC7757557 | biostudies-literature
| S-EPMC8543085 | biostudies-literature
| S-EPMC9040117 | biostudies-literature
| S-EPMC10635898 | biostudies-literature